Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.). [electronic resource]
Producer: 19970226Description: 821-6 p. digitalISSN:- 0923-7534
- Adult
- Aged
- Antibiotics, Antineoplastic -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Agents, Phytogenic
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cisplatin -- administration & dosage
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Etoposide -- administration & dosage
- Female
- Humans
- Infusions, Intravenous
- Lung Neoplasms -- diagnosis
- Male
- Middle Aged
- Mitomycin -- administration & dosage
- Multivariate Analysis
- Survival Rate
- Treatment Outcome
- Vindesine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.